Unnamed: 0,title,date,stock,sentiment
1041513.0,Portola Pharmaceuticals Option Alert: Jan 15 $17.5 Puts Sweep (8) near the Bid: 504 @ $0.25 vs 7198 OI; Ref=$17.835,2020-05-22 10:34:00-04:00,PTLA,positive
1041514.0,UPDATE: Elliott's Letter To Alexion Board,2020-05-12 08:57:00-04:00,PTLA,neutral
1041515.0,"Elliott Advisors Says Portola's 'Lack Of Obvious Strategic Fit' With Alexion Is What Drove 'Bulk Of The Market's Negative Reaction, In Our View'",2020-05-12 08:42:00-04:00,PTLA,negative
1041516.0,"Portola Pharma Shares Volatile, Very Slightly Lower, Following Letter From Elliott Advisors To Alexion Criticizing Deal With Co.",2020-05-12 08:38:00-04:00,PTLA,negative
1041517.0,Portola Pharma Cut FY20 Opex Guidance By ~$50M,2020-05-11 08:25:00-04:00,PTLA,negative
1041518.0,"Portola Pharmaceuticals Q1 EPS $(0.880) Misses $(0.800) Estimate, Sales $26.389M Miss $33.860M Estimate",2020-05-11 08:23:00-04:00,PTLA,negative
1041519.0,"Morgan Stanley Maintains Equal-Weight on Portola Pharmaceuticals, Raises Price Target to $18",2020-05-08 08:58:00-04:00,PTLA,neutral
1041520.0,70 Biggest Movers From Yesterday,2020-05-06 05:26:00-04:00,PTLA,neutral
1041521.0,Mid-Afternoon Market Update: NASDAQ Surges More Than 2%; Itron Shares Slide,2020-05-05 14:40:00-04:00,PTLA,positive
1041522.0,51 Stocks Moving In Tuesday's Mid-Day Session,2020-05-05 12:22:00-04:00,PTLA,neutral
1041523.0,Mid-Day Market Update: Crude Oil Jumps 19%; Fulgent Genetics Shares Plunge Following Q1 Earnings,2020-05-05 12:00:00-04:00,PTLA,negative
1041524.0,Portola Pharmaceuticals: P/E Ratio Insights,2020-05-05 10:50:00-04:00,PTLA,neutral
1041525.0,Mid-Morning Market Update: Markets Open Higher; Sysco Misses Q3 Views,2020-05-05 10:36:00-04:00,PTLA,negative
1041526.0,What You Should Know About Alexion's $1.4B Proposed Buyout Of Portola Pharma,2020-05-05 09:10:00-04:00,PTLA,neutral
1041527.0,Portola Pharmaceuticals shares are trading higher after the company announced it will be acquired by Alexion for $18 per share in cash.,2020-05-05 07:47:00-04:00,PTLA,positive
1041528.0,Alexion Reports Purchase Of Portola Pharma For $18/Share In Cash,2020-05-05 07:15:00-04:00,PTLA,neutral
1041529.0,Portola Pharmaceuticals shares are trading higher after RBC analysts initiated coverage on the company with an Outperform rating and $20 price target.,2020-04-23 09:08:00-04:00,PTLA,positive
1041530.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-23 07:31:00-04:00,PTLA,neutral
1041531.0,"RBC Capital Initiates Coverage On Portola Pharmaceuticals with Outperform Rating, Announces Price Target to $20",2020-04-23 07:18:00-04:00,PTLA,neutral
1041532.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 11:47:00-04:00,PTLA,positive
1041533.0,Portola Pharmaceuticals Option Alert: Apr 17 $7.5 Calls Sweep (3) near the Ask: 813 @ $0.3 vs 7860 OI; Earnings 5/6 Before Open [est] Ref=$6.48,2020-04-01 13:02:00-04:00,PTLA,positive
1041534.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,PTLA,positive
1041535.0,Portola Pharmaceuticals announces Proactive Steps Including Suspending Face-To-Face Field Activity and Instituted A Mandatory Work From Home Policy For All Employees,2020-03-18 16:15:00-04:00,PTLA,positive
1041536.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,PTLA,positive
1041537.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PTLA,neutral
1041538.0,Portola Pharmaceuticals shares are trading lower despite the company announcing the results of its Andexxa. NOTE: The overall market is trading lower amid continued coronavirus fears hampering the global economy.,2020-03-16 11:36:00-04:00,PTLA,negative
1041539.0,Portola Pharmaceuticals Announces Results Demonstrating Andexxa Was 'Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds',2020-03-16 08:16:00-04:00,PTLA,negative
1041540.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,PTLA,negative
1041541.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,PTLA,negative
1041542.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,PTLA,negative
1041543.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,PTLA,positive
1041544.0,Stocks That Hit 52-Week Lows On Tuesday,2020-03-10 10:37:00-04:00,PTLA,negative
1041545.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,PTLA,negative
1041546.0,Portola Pharma Highlights Presentation Of New Data Showing Andexxa To Treat Patients With ICH At Emergencies In Medicine Meeting,2020-03-05 08:35:00-05:00,PTLA,positive
1041547.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,PTLA,positive
1041548.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,PTLA,negative
1041549.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,PTLA,neutral
1041550.0,140 Biggest Movers From Yesterday,2020-02-28 05:00:00-05:00,PTLA,neutral
1041551.0,100 Stocks Moving In Thursday's Mid-Day Session,2020-02-27 12:24:00-05:00,PTLA,neutral
1041552.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,PTLA,negative
1041553.0,Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.,2020-02-27 09:28:00-05:00,PTLA,negative
1041554.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,PTLA,positive
1041555.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,PTLA,negative
1041556.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,PTLA,negative
1041557.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,PTLA,neutral
1041558.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,PTLA,negative
1041559.0,Stocks That Hit 52-Week Lows On Thursday,2020-01-30 10:54:00-05:00,PTLA,negative
1041560.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,PTLA,positive
1041561.0,Stocks That Hit 52-Week Lows On Monday,2020-01-27 10:42:00-05:00,PTLA,negative
1041562.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,PTLA,negative
1041563.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,PTLA,neutral
1041564.0,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet,2020-01-10 14:41:00-05:00,PTLA,positive
1041565.0,40 Stocks Moving In Friday's Mid-Day Session,2020-01-10 12:29:00-05:00,PTLA,neutral
1041566.0,Stocks That Hit 52-Week Lows On Friday,2020-01-10 12:24:00-05:00,PTLA,negative
1041567.0,"Benzinga's Top Upgrades, Downgrades For January 10, 2020",2020-01-10 12:16:00-05:00,PTLA,positive
1041568.0,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump,2020-01-10 12:13:00-05:00,PTLA,negative
1041569.0,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share,2020-01-10 10:14:00-05:00,PTLA,neutral
1041570.0,10 Biggest Price Target Changes For Friday,2020-01-10 08:37:00-05:00,PTLA,neutral
1041571.0,Portola Pharmaceuticals shares are trading lower after the company reported preliminary FY19 Andexxa global net revenues of $111 million.,2020-01-10 07:52:00-05:00,PTLA,neutral
1041572.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-01-10 07:38:00-05:00,PTLA,neutral
1041573.0,"Oppenheimer Downgrades Portola Pharmaceuticals to Perform, Lowers Price Target to $17",2020-01-10 07:35:00-05:00,PTLA,negative
1041574.0,33 Stocks Moving in Friday's Pre-Market Session,2020-01-10 07:26:00-05:00,PTLA,neutral
1041575.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,PTLA,positive
1041576.0,Portola Pharmaceuticals shares are trading lower after the company reported preliminary FY19 Andexxa global net revenues of $111 million.,2020-01-09 16:05:00-05:00,PTLA,neutral
1041577.0,Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million,2020-01-09 16:03:00-05:00,PTLA,neutral
1041578.0,Portola Pharma Highlights Presentation Of New Interim Data On Oral Cerdulatinib At ASH,2019-12-09 15:23:00-05:00,PTLA,neutral
1041579.0,Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies,2019-12-08 15:55:00-05:00,PTLA,negative
1041580.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,PTLA,positive
1041581.0,Goldman Sachs Initiates Coverage On Portola Pharmaceuticals with Neutral Rating,2019-11-08 06:36:00-05:00,PTLA,neutral
1041582.0,Portola Pharmaceuticals shares are trading lower despite the company reporting better-than-expected Q3 EPS and sales results.,2019-11-06 13:51:00-05:00,PTLA,neutral
1041583.0,"Portola Pharmaceuticals Q3 EPS $(0.68) Beats $(0.82) Estimate, Sales $36.8M Beat $34.63M Estimate",2019-11-05 16:00:00-05:00,PTLA,neutral
1041584.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,PTLA,negative
1041585.0,Portola Pharmaceuticals To Present New Analysis From ANNEXA-4 Study Of Its Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Acute Gastrointestinal Bleeding At American College Of Gastroenterology Oct. 29,2019-10-28 09:12:00-04:00,PTLA,negative
1041586.0,"Citigroup Maintains Buy on Portola Pharmaceuticals, Lowers Price Target to $44",2019-10-09 08:53:00-04:00,PTLA,negative
1041587.0,32 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-08-14 08:50:00-04:00,PTLA,neutral
1041588.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-08-13 12:32:00-04:00,PTLA,neutral
1041589.0,31 Stocks Moving In Tuesday's Pre-Market Session,2019-08-13 08:21:00-04:00,PTLA,neutral
1041590.0,A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Consumer Price Index,2019-08-13 07:29:00-04:00,PTLA,negative
1041591.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,PTLA,neutral
1041592.0,"7 Stocks To Watch For August 13, 2019",2019-08-13 04:40:00-04:00,PTLA,neutral
1041593.0,8 Stocks Moving In Monday's After-Hours Session,2019-08-12 17:22:00-04:00,PTLA,neutral
1041594.0,Portola Pharma shares are trading lower after the company reported a $200 million common stock offering.,2019-08-12 16:46:00-04:00,PTLA,neutral
1041595.0,Portola Pharma Reports $200M Common Stock Offering,2019-08-12 16:44:00-04:00,PTLA,neutral
1041596.0,110 Biggest Movers From Yesterday,2019-08-09 05:15:00-04:00,PTLA,neutral
1041597.0,90 Stocks Moving In Thursday's Mid-Day Session,2019-08-08 12:50:00-04:00,PTLA,neutral
1041598.0,Portola Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-08 11:32:00-04:00,PTLA,positive
1041599.0,52 Stocks Moving In Thursday's Pre-Market Session,2019-08-08 07:49:00-04:00,PTLA,neutral
1041600.0,Portola Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-07 17:00:00-04:00,PTLA,positive
1041601.0,"Portola Pharmaceuticals Q2 EPS $(0.97) Beats $(1.03) Estimate, Sales $28.4M Beat $25.54M Estimate",2019-08-07 16:59:00-04:00,PTLA,neutral
1041602.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,PTLA,neutral
1041603.0,Portola Announces First European Orders For Ondexxya (Andexanet Alfa),2019-08-06 08:38:00-04:00,PTLA,neutral
1041604.0,"Credit Suisse Assumes Portola Pharmaceuticals at Neutral, Announces $35 Price Target",2019-08-05 08:33:00-04:00,PTLA,positive
1041605.0,Portola Pharma Announces that the US Centers for Medicare and Medicaid Services Has Increased the Maximum Reimbursement Amount for the New Technology Add-on Payment Granted in October 2018 to Andexxa,2019-08-05 07:18:00-04:00,PTLA,positive
1041606.0,Credit Suisse Assumes Portola Pharmaceuticals at Neutral,2019-07-10 09:22:00-04:00,PTLA,positive
1041607.0,Portola Pharmaceuticals Highlights Presentation Of New In Vitro Data Demonstrating That Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors,2019-07-08 08:31:00-04:00,PTLA,negative
1041608.0,Portola Pharma Highlights New Interim Data On Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma,2019-06-19 11:06:00-04:00,PTLA,negative
1041609.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,PTLA,negative
1041610.0,Portola Pharmaceuticals Announces New Analysis From The Annexa-4 Study Of Its Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Spontaneous Intracranial Hemorrhage; Excellent Or Good Hemostasis Achieved In 79% Of Evaluable Patients,2019-05-22 10:47:00-04:00,PTLA,positive
1041611.0,31 Stocks Moving In Monday's Pre-Market Session,2019-05-20 08:13:00-04:00,PTLA,neutral
1041612.0,"Portola Pharmaceuticals Q1 EPS $(1.02) Up From $(1.28) YoY, Sales $22.169M Up From $6.644M YoY",2019-05-08 09:26:00-04:00,PTLA,neutral
1041613.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,PTLA,negative
1041614.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,PTLA,neutral
1041615.0,Portola Pharmaceuticals Announces That The European Commission Has Granted Conditional Marketing Authorization For Ondexxya; Initial Launch In Select Countries To Begin 2H 201,2019-04-26 14:02:00-04:00,PTLA,positive
1041616.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,PTLA,negative
1041617.0,Portola Pharma Reports Co-Founder Charles Homey Retires; Board Has Engaged Search For New Independent Director,2019-03-20 17:04:00-04:00,PTLA,positive
1041618.0,81 Biggest Movers From Friday,2019-03-04 05:39:00-05:00,PTLA,neutral
1041619.0,64 Stocks Moving In Friday's Mid-Day Session,2019-03-01 13:18:00-05:00,PTLA,neutral
1041620.0,Portola Pharma shares are trading higher after the company announced its Ondexxya recieved a positive opinion from Europe's Committee for Medicinal Products.,2019-03-01 08:52:00-05:00,PTLA,positive
1041621.0,30 Stocks Moving In Friday's Pre-Market Session,2019-03-01 08:09:00-05:00,PTLA,neutral
1041622.0,Portola Pharma Reports CHMP Positive Opinion On Ondexxya,2019-03-01 07:43:00-05:00,PTLA,positive
1041623.0,"Earnings Scheduled For March 1, 2019",2019-03-01 04:01:00-05:00,PTLA,neutral
1041624.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,PTLA,neutral
1041625.0,Portola Pharmaceuticals Announces Full Results From ANNEXA-4 Study Of Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Life-Threatening Bleeding; Achieved 'Excellent Or Good' Homeostasis In 82% Of Patients,2019-02-07 16:51:00-05:00,PTLA,positive
1041626.0,50 Biggest Movers From Monday,2019-01-02 04:48:00-05:00,PTLA,neutral
1041627.0,"Portola Pharma Shares Resume, Up 7% For Session",2018-12-31 15:40:00-05:00,PTLA,positive
1041628.0,Portola Pharma Shares To Resume Trade At 3:40 p.m. EST,2018-12-31 15:26:00-05:00,PTLA,positive
1041629.0,Portola Sees Full Commercial Launch Of Andexxa Gen 2 Manufacturing Process Beginning Jan. 2019,2018-12-31 15:20:00-05:00,PTLA,neutral
1041630.0,FDA Approves Portola Pharma's Prior Approval Supplement For Andexxa Gen-2 Manufacturing Process,2018-12-31 15:19:00-05:00,PTLA,positive
1041631.0,Portola Pharma Shares Halted Ahead Of PDUFA Announcement For Gen-2 Andrexxa,2018-12-31 14:40:00-05:00,PTLA,positive
1041632.0,Portola Pharma Shares Halted News Pending,2018-12-31 14:33:00-05:00,PTLA,positive
1041633.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,PTLA,neutral
1041634.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,PTLA,neutral
1041635.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,PTLA,neutral
1041636.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,PTLA,positive
1041637.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,PTLA,positive
1041638.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,PTLA,neutral
1041639.0,"Portola Pharmaceuticals shares are trading lower after the CHMP, a committee of the European Medicines Agency, announced it has extended the review period for the company's marketing authorization application for Ondexxya and delayed the Oral Explanation.",2018-12-11 14:45:00-05:00,PTLA,negative
1041640.0,European Medicines Agency Committee Extends Review Period For Portola Pharmaceuticals' Ondexxya,2018-12-11 07:12:00-05:00,PTLA,positive
1041641.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,PTLA,neutral
1041642.0,Portola Pharmaceuticals Presents Updated Interim Results from Ongoing Phase 2a Study of  Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses  in Heavily Pre-Treated T-Cell Malignancies at ASH 2018,2018-12-04 04:45:00-05:00,PTLA,negative
1041643.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,PTLA,neutral
1041644.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2018-11-30 13:09:00-05:00,PTLA,neutral
1041645.0,80 Biggest Movers From Yesterday,2018-11-09 05:18:00-05:00,PTLA,neutral
1041646.0,65 Stocks Moving In Thursday's Mid-Day Session,2018-11-08 12:51:00-05:00,PTLA,neutral
1041647.0,Mid-Day Market Update: Dow Turns Higher; Koppers Holdings Shares Drop Following Weak Q3 Results,2018-11-08 12:10:00-05:00,PTLA,negative
1041648.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,PTLA,negative
1041649.0,Mid-Morning Market Update: Markets Open Lower; Cardinal Health Tops Q1 Views,2018-11-08 10:30:00-05:00,PTLA,positive
1041650.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,PTLA,negative
1041651.0,35 Stocks Moving In Thursday's Pre-Market Session,2018-11-08 08:02:00-05:00,PTLA,neutral
1041652.0,"Portola Pharma Q3 EPS $(1.08) Beats $(1.62) Estimate, Sales $14.177M Beat $7.1M Estimate",2018-11-07 16:49:00-05:00,PTLA,neutral
1041653.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,PTLA,negative
1041654.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,PTLA,neutral
1041655.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,PTLA,negative
1041656.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,PTLA,negative
1041657.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,PTLA,negative
1041658.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,PTLA,positive
1041659.0,Portola Pharmaceuticals 13G Shows Deerfield Management Raised Stake In Co. From ~1.45M Shares To ~3.55M Shares,2018-10-18 15:24:00-04:00,PTLA,positive
1041660.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,PTLA,negative
1041661.0,"Stocks Which Set New 52-Week Low Yesterday, October 2nd",2018-10-03 13:01:00-04:00,PTLA,negative
1041662.0,"Portola Pharmaceuticals Receives FDA Orphan Drug Designation For Cerdulatinib, An Oral Syk/JAK Inhibitor For Treatment Of Peripheral T-Cell Lymphoma",2018-09-25 16:39:00-04:00,PTLA,negative
1041663.0,Portola Pharmaceuticals Names Scott Garland President And CEO,2018-09-20 08:31:00-04:00,PTLA,neutral
1041664.0,FDA Late Tuesday Announced December 31 PDUFA Date For Portola Pharmaceuticals' Prior Approval Supplement For Generation 2 Andexxa Manufacturing Process,2018-09-12 08:39:00-04:00,PTLA,positive
1041665.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,PTLA,positive
1041666.0,"FDA Assigns PDUFA Date December 31, 2018 to Portola Pharmaceuticals' Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process",2018-09-11 20:55:00-04:00,PTLA,positive
1041667.0,Portola Pharmaceuticals Submits Prior Approval Supplement To FDA For Large-Scale Generation 2 Andexxa Manufacturing Process,2018-08-31 08:31:00-04:00,PTLA,positive
1041668.0,Sympathy Move: Portola Upgraded After Competitor Reports Sour Data,2018-08-27 10:31:00-04:00,PTLA,positive
1041669.0,6 Biggest Price Target Changes For Monday,2018-08-27 09:54:00-04:00,PTLA,neutral
1041670.0,"Benzinga's Top Upgrades, Downgrades For August 27, 2018",2018-08-27 09:31:00-04:00,PTLA,positive
1041671.0,24 Stocks Moving In Monday's Pre-Market Session,2018-08-27 08:40:00-04:00,PTLA,neutral
1041672.0,"Credit Suisse Upgrades Portola Pharmaceuticals to Neutral, Raises Price Target to $34",2018-08-27 06:00:00-04:00,PTLA,positive
1041673.0,"Insider Buys Of The Week: Andeavor, Corcept, Portola",2018-08-25 18:01:00-04:00,PTLA,neutral
1041674.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-08-21 08:02:00-04:00,PTLA,neutral
1041675.0,"Stocks Which Set New 52-Week Low Yesterday, August 16th",2018-08-17 10:40:00-04:00,PTLA,negative
1041676.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,PTLA,negative
1041677.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,PTLA,negative
1041678.0,"Stocks Which Set New 52-Week Low Yesterday, August 14th",2018-08-15 12:34:00-04:00,PTLA,negative
1041679.0,"The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut",2018-08-14 08:23:00-04:00,PTLA,neutral
1041680.0,10 Biggest Price Target Changes For Friday,2018-08-10 09:59:00-04:00,PTLA,neutral
1041681.0,"Benzinga's Top Upgrades, Downgrades For August 10, 2018",2018-08-10 09:17:00-04:00,PTLA,positive
1041682.0,"Credit Suisse Downgrades Portola Pharmaceuticals to Underperform, Lowers Price Target to $28",2018-08-10 06:17:00-04:00,PTLA,positive
1041683.0,77 Biggest Movers From Yesterday,2018-08-10 04:01:00-04:00,PTLA,neutral
1041684.0,68 Stocks Moving In Thursday's Mid-Day Session,2018-08-09 12:41:00-04:00,PTLA,neutral
1041685.0,Portola Pharmaceuticals shares are trading 17% lower to $31.31 after the company reported weak quarterly financial results.,2018-08-09 12:12:00-04:00,PTLA,negative
1041686.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,PTLA,positive
1041687.0,"Portola Pharmaceuticals Q2 EPS $(1.61) Misses $(1.49) Estimate, Sales $4.011M Miss $6.35M Estimate",2018-08-09 08:02:00-04:00,PTLA,negative
1041688.0,Portola Pharma's Q2 Earnings Outlook,2018-08-08 10:18:00-04:00,PTLA,neutral
1041689.0,"UPDATE: Portola Pharma Interim Co-Pres Said, 'will maintain focus on the U.S. commercial launch as we continue to work toward our goal of expanding patient access to betrixaban around the world'",2018-07-27 08:28:00-04:00,PTLA,neutral
1041690.0,Portola Pharma Reports CHMP Maintains Negative Opinion On Betrixaban Following Appeal,2018-07-27 08:27:00-04:00,PTLA,negative
1041691.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,PTLA,positive
1041692.0,Portola Pharma Reports CEO Bill Lis To Retire; Board Has Begun Active Search For Replacement,2018-06-04 16:34:00-04:00,PTLA,positive
1041693.0,"Portola Pharmaceuticals Announces Interim Phase 2a Results For Oral SYK/JAK Inhibitor Cerdulatinib, Shows Efficacy In Patients and Demonstrates 'Broad Clinical Activity'",2018-06-04 08:40:00-04:00,PTLA,negative
1041694.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,PTLA,negative
1041695.0,Portola Pharmaceuticals Receives $100M Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa,2018-05-24 08:31:00-04:00,PTLA,positive
1041696.0,"Jim Cramer Shares His Thoughts On Xerox, Booking Holdings And More",2018-05-14 07:15:00-04:00,PTLA,positive
1041697.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,PTLA,neutral
1041698.0,"Portola Pharmaceuticals Q1 EPS $(1.28) Beats $(1.52) Estimate, Sales $6.644M Beat $4.03M Estimate",2018-05-09 16:09:00-04:00,PTLA,neutral
1041699.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,PTLA,neutral
1041700.0,43 Biggest Movers From Friday,2018-05-07 06:28:00-04:00,PTLA,neutral
1041701.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,PTLA,neutral
1041702.0,Mid-Afternoon Market Update: Dow Surges Around 400 Points; Portola Pharmaceuticals Shares Spike Higher,2018-05-04 14:58:00-04:00,PTLA,positive
1041703.0,Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote,2018-05-04 14:14:00-04:00,PTLA,positive
1041704.0,38 Stocks Moving In Friday's Mid-Day Session,2018-05-04 13:49:00-04:00,PTLA,neutral
1041705.0,Mid-Day Market Update: Crude Oil Up 2%; Fluor Shares Plummet,2018-05-04 13:00:00-04:00,PTLA,negative
1041706.0,Portola Pharmaceuticals Shares Up 21.2% On FDA Approval of Andexxa,2018-05-04 11:45:00-04:00,PTLA,positive
1041707.0,Mid-Morning Market Update: Markets Open Higher; Alibaba Tops Q4 Estimates,2018-05-04 10:23:00-04:00,PTLA,positive
1041708.0,Benzinga Pro's 5 Stocks To Watch Today,2018-05-04 09:27:00-04:00,PTLA,neutral
1041709.0,"Benzinga Pro's Most-Searched Tickers For Morning Of Fri., May 4, 2018",2018-05-04 09:15:00-04:00,PTLA,neutral
1041710.0,"Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down",2018-05-04 08:16:00-04:00,PTLA,neutral
1041711.0,33 Stocks Moving In Friday's Pre-Market Session,2018-05-04 08:03:00-04:00,PTLA,neutral
1041712.0,UPDATE: Portola Pharma Shares Now Up 25.5%,2018-05-04 07:16:00-04:00,PTLA,positive
1041713.0,"Portola Pharma Shares Resume Trade, Now Indicated Up 3.3%",2018-05-04 07:16:00-04:00,PTLA,positive
1041714.0,Portola Pharma Shares To Resume Trade At 7:15 a.m. EDT,2018-05-04 06:54:00-04:00,PTLA,positive
1041715.0,Portola Pharma Shares Were Halted Ahead Of News FDA Approved Andexxa For Reversal Of Factor Xa Inhibitors,2018-05-04 06:22:00-04:00,PTLA,positive
1041716.0,"FDA Approves Portola Pharmaceuticals' Andexxa, Antidote for Reversal of Factor Xa Inhibitors",2018-05-04 04:09:00-04:00,PTLA,positive
1041717.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates,2018-05-01 15:39:00-04:00,PTLA,neutral
1041718.0,Portola Pharm Option Alert: May 18 $55 Calls Sweep (2) at the Bid: 879 @ $0.7 vs 17326 OI; Earnings 5/7 After Close [est] Ref=$36.765,2018-04-30 15:05:00-04:00,PTLA,positive
1041719.0,"The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More",2018-04-30 12:56:00-04:00,PTLA,neutral
1041720.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,PTLA,neutral
1041721.0,20 Stocks Moving In Monday's Pre-Market Session,2018-04-09 08:06:00-04:00,PTLA,neutral
1041722.0,"Portola Pharma Reports CHMP Issued Negative Opinion For Betrixaban For Prevention Of VTE In Adults For Acute Medical Illness; Co. To Appeal Opinion, Seek Re-Examination",2018-03-23 09:14:00-04:00,PTLA,negative
1041723.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,PTLA,neutral
1041724.0,45 Biggest Movers From Yesterday,2018-03-02 05:03:00-05:00,PTLA,neutral
1041725.0,Mid-Afternoon Market Update: Dow Falls Over 300 Points; AxoGen Shares Spike Higher,2018-03-01 14:31:00-05:00,PTLA,positive
1041726.0,Portola Pharmaceuticals Shares Down 25% As News Of Potential Delay Of U.S. Approval Of AndexXa Overshadows Q4 Earnings Beat,2018-03-01 14:10:00-05:00,PTLA,positive
1041727.0,34 Stocks Moving In Thursday's Mid-Day Session,2018-03-01 12:43:00-05:00,PTLA,neutral
1041728.0,Mid-Day Market Update: U.S. Stocks Turn Lower; Novavax Shares Gain On Positive Data,2018-03-01 12:21:00-05:00,PTLA,positive
1041729.0,FDA Risk For Portola Pharma's Thrombosis Treatment Sends Morgan Stanley To Sideline,2018-03-01 11:01:00-05:00,PTLA,negative
1041730.0,Mid-Morning Market Update: Markets Gain; Best Buy Beats Q4 Estimates,2018-03-01 10:36:00-05:00,PTLA,positive
1041731.0,"Benzinga's Top Upgrades, Downgrades For March 1, 2018",2018-03-01 09:46:00-05:00,PTLA,positive
1041732.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-03-01 08:02:00-05:00,PTLA,neutral
1041733.0,Morgan Stanley Downgrades Portola Pharmaceuticals to Equal-Weight,2018-03-01 07:47:00-05:00,PTLA,neutral
1041734.0,"Portola Pharma Reports Q4 EPS $(1.41) vs $(1.46) Est., Collaboration, License Sales $9.8M vs $6.2M Est.",2018-02-28 16:14:00-05:00,PTLA,neutral
1041735.0,Portola Pharmaceuticals Q4 Earnings Preview,2018-02-28 08:17:00-05:00,PTLA,neutral
1041736.0,"Morgan Stanley Maintains Overweight on Portola Pharmaceuticals, Lowers price target to $65.00",2018-02-22 10:06:00-05:00,PTLA,negative
1041737.0,"Credit Suisse Maintains Outperform on Portola Pharmaceuticals, Lowers price target to $53.00",2018-02-21 08:30:00-05:00,PTLA,positive
1041738.0,Portola Pharmaceuticals Announces CHMP Of EMA Has Communicated A Positive Trend Vote On The MAA For andexanet alfa,2018-02-20 16:49:00-05:00,PTLA,positive
1041739.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,PTLA,neutral
1041740.0,Portola Pharmaceuticals Late Monday Announced Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18,2018-01-23 09:47:00-05:00,PTLA,positive
1041741.0,Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18,2018-01-23 03:54:00-05:00,PTLA,positive
1041742.0,How To Trade The JPMorgan Healthcare Conference,2018-01-08 13:19:00-05:00,PTLA,neutral
1041743.0,Portola Pharma Option Alert: Jan 19 $50 Calls Sweep (2) at the Ask: 1000 @ $2.0 vs 672 OI; Ref=$49.94,2018-01-04 10:50:00-05:00,PTLA,positive
1041744.0,32 Biggest Movers From Yesterday,2017-12-27 04:59:00-05:00,PTLA,neutral
1041745.0,Mid-Afternoon Market Update: Crude Oil Up 2.5%; Aptose Biosciences Shares Spike Higher,2017-12-26 14:54:00-05:00,PTLA,negative
1041746.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-12-26 14:20:00-05:00,PTLA,neutral
1041748.0,Portola Pharma Shares Under Pressure After FDA Extension,2017-12-26 10:18:00-05:00,PTLA,neutral
1041749.0,Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa,2017-12-22 17:51:00-05:00,PTLA,neutral
1041750.0,Oppenheimer Serves Up 29 Top Stock Ideas For January,2017-12-19 17:43:00-05:00,PTLA,positive
1041751.0,UPDATE: Portola Shares Up 3.7% For Session,2017-12-19 10:37:00-05:00,PTLA,positive
1041752.0,"Portola Pharma Shares At Session Highs, Spike Over $49 Level Amid News FDA Approved Co.'s Prior Approval Supplement for Commercial Launch Of Bevyxxa",2017-12-19 10:36:00-05:00,PTLA,positive
1041753.0,"Portola Pharma Shares Not Reacting Following Oppenheimer Mid-Day Commentary Related To CHMP's Request For Added Info On Betrixaban MAA, Highlights Issues 'pertain strictly to betrixaban clinical data and not manufacturing'",2017-12-13 10:19:00-05:00,PTLA,positive
1041754.0,Portola Pharma Says the European Medicines Agency Has Requested Additional Information Related to the Marketing Authorization Application for Betrixaban,2017-12-12 08:32:00-05:00,PTLA,neutral
1041755.0,"Goldman Sachs Initiates Coverage On Portola Pharmaceuticals with Buy Rating, Announces $75.00 Price Target",2017-12-01 08:27:00-05:00,PTLA,neutral
1041756.0,Portola Pharma Offers Update On Bevyxxa Launch: FDA Has Extended Review Period To Allow Agency Time To Review The Entire Submission,2017-11-21 18:25:00-05:00,PTLA,positive
1041757.0,"Portola Pharma Reports Q3 EPS $(1.41) vs $(1.46) Est., Collaboration, License Sales $3.8M vs $9.3M In Same Qtr. Last Year",2017-11-06 16:36:00-05:00,PTLA,neutral
1041758.0,Portola Pharmaceuticals Names Dr. John Lawrence Chief Medical Officer,2017-11-06 08:05:00-05:00,PTLA,neutral
1041759.0,Jim Cramer Advises His Viewers On Southwest Airlines And General Electric,2017-09-27 07:35:00-04:00,PTLA,neutral
1041760.0,15 Biggest Mid-Day Losers For Tuesday,2017-09-19 12:45:00-04:00,PTLA,negative
1041761.0,Portola Pharma Shares Tick ~$0.35 Higher Over Last Few Mins As Traders Circulate Word Of Citi Defense On Name,2017-09-19 12:04:00-04:00,PTLA,positive
1041762.0,"Stat's Adam Feuerstein Tweets: $PTLA $350M financing done by MS, Citi, GS — none of which bothered to ask about or look up new VTE clinical guidelines? Sloppy!",2017-09-19 11:39:00-04:00,PTLA,positive
1041763.0,Stat's Adam Feuerstein Tweets: $PTLA -11% today in part bc of my article but also investor anger. Company raised a lot of money w/o disclosing existence new guidelines.,2017-09-19 11:37:00-04:00,PTLA,negative
1041764.0,Stat News Tweets: Commercial launch of Portola's new blood thinner could be threatened by new clinical guidelines ,2017-09-19 09:36:00-04:00,PTLA,negative
1041765.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-19 08:10:00-04:00,PTLA,neutral
1041766.0,Portola Prices 6.35M Share Offering @$55.00/Share,2017-09-13 04:19:00-04:00,PTLA,positive
1041767.0,Portola Pharma Announces $300M Offering Common Stock,2017-09-11 16:01:00-04:00,PTLA,neutral
1041768.0,"Lightning Round: Jim Cramer Shares His Thoughts On Kite Pharma, Bank Of America And More",2017-08-25 07:38:00-04:00,PTLA,positive
1041769.0,"Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva",2017-08-24 13:46:00-04:00,PTLA,positive
1041770.0,The Market In 5 Minutes,2017-08-24 10:01:00-04:00,PTLA,neutral
1041771.0,"Benzinga's Top Upgrades, Downgrades For August 24, 2017",2017-08-24 09:19:00-04:00,PTLA,positive
1041772.0,Credit Suisse Upgrades Portola Pharmaceuticals to Outperform,2017-08-24 05:56:00-04:00,PTLA,positive
1041773.0,Portola Pharma Reports AndexXa BLA Resubmission Accepted For Review By FDA,2017-08-15 08:00:00-04:00,PTLA,positive
1041774.0,"Portola Pharmaceuticals Reports Q2 EPS $(1.22) vs $(0.98) Est., Sales $3.787M vs $8.84M Est.",2017-08-09 16:33:00-04:00,PTLA,neutral
1041775.0,Portola Pharmaceuticals Reports Resubmission of Biologics License Application for AndexXa,2017-08-03 16:13:00-04:00,PTLA,neutral
1041776.0,Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days,2017-07-05 11:01:00-04:00,PTLA,neutral
1041777.0,"A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside",2017-06-26 14:03:00-04:00,PTLA,positive
1041778.0,Portola Pharmaceuticals: Expect Additional Upside From Here,2017-06-26 10:56:00-04:00,PTLA,neutral
1041780.0,Mid-Afternoon Market Update: Portola Climbs On FDA Approval For Bevyxxa; American Software Shares Plunge,2017-06-23 14:30:00-04:00,PTLA,positive
1041781.0,"Portola Pharma Shares Resume Trading, Now Up 45%",2017-06-23 13:38:00-04:00,PTLA,positive
1041782.0,Portola Receives FDA Approval For Bevyxxa,2017-06-23 13:22:00-04:00,PTLA,positive
1041783.0,Portola Pharma Shares To Resume Trading At 1:35pm ET,2017-06-23 13:14:00-04:00,PTLA,positive
1041784.0,"UPDATE: Portola PR Confirms FDA Approval Of Bevyxxa (betrixaban), Co. Expects To Launch Between August And November 2017",2017-06-23 13:06:00-04:00,PTLA,positive
1041785.0,Portola Received FDA Approval For Bevyxxa In Acutely Ill Patients Not Undergoing Surgery,2017-06-23 12:11:00-04:00,PTLA,positive
1041786.0,Traders Circulate FDA Document Appearing To Show FDA Approval For Portola Pharma's Betrixaban,2017-06-23 11:55:00-04:00,PTLA,positive
1041787.0,"Portola Pharma Shares Halted, News Pending; BZ Note: Co. Has FDA PDUFA Date Tomorrow",2017-06-23 11:19:00-04:00,PTLA,positive
1041788.0,Citi Says Expect FDA PDUFA Decision For Portola Pharma Early,2017-06-23 10:52:00-04:00,PTLA,neutral
1041789.0,"European Hematology Association (EHA) Congress 2017 Continues Today, Bellicum Pharma Expected To Present",2017-06-23 08:22:00-04:00,PTLA,neutral
1041790.0,"European Hematology Association (EHA) Congress 2017 Begins Today, Day 1 of 4",2017-06-22 08:47:00-04:00,PTLA,neutral
1041791.0,15 Stocks Moving In Monday's Pre-Market Session,2017-06-19 08:37:00-04:00,PTLA,neutral
1041792.0,Tracking The Busy June PDUFA Calendar,2017-05-30 08:58:00-04:00,PTLA,neutral
1041793.0,"Portola Pharma Reports Q1 EPS $(0.74) vs $(0.69) Est., Sales $5.128M May Not Compare To $20.46M Est.",2017-05-08 16:38:00-04:00,PTLA,neutral
1041794.0,Watch These 8 Huge Call Purchases In Monday Trade,2017-04-10 06:52:00-04:00,PTLA,positive
1041795.0,Benzinga's Option Alert Recap From April 7,2017-04-07 16:30:00-04:00,PTLA,positive
1041796.0,Option Alert: Portola Pharm May 40.0 Calls: 4770 @  ASK  $1.80: 5853 traded vs 15 OI:  Earnings 5/4 After Close [est]  $35.95 Ref,2017-04-07 12:07:00-04:00,PTLA,positive
1041797.0,Portola Pharmaceuticals Reports Q4 EPS $(0.95) vs. $(1.12) Est.,2017-02-28 16:47:00-05:00,PTLA,neutral
1041798.0,Oppenheimer Upgrades Portola Pharmaceuticals To Outperform,2017-02-24 08:55:00-05:00,PTLA,neutral
1041799.0,Portola Pharmaceuticals Reports FDA Has Told Co. It Hasn't Identified Issues At Mid-Cycle Review With Betrixaban That Require An Advisory Meeting,2017-02-08 08:03:00-05:00,PTLA,neutral
1041800.0,"Portola Pharma Reports Signing of $150M Royalty Deal with HealthCare Royalty Partners for Development, Commercialization of Andexanet Alfa",2017-02-03 08:04:00-05:00,PTLA,neutral
1041801.0,"Oppenheimer Initiates Coverage On Portola Pharmaceuticals at Perform, Announces $28.00 Target",2017-01-19 16:39:00-05:00,PTLA,neutral
1041802.0,18 Stocks Moving In Friday's Pre-Market Session,2017-01-13 08:08:00-05:00,PTLA,neutral
1041803.0,"UPDATE: William Blair on Portola: Sees Two Drug Approvals in 2017, Says Andexxa, Betrixaban Worth At Least $100/Share",2017-01-05 10:06:00-05:00,PTLA,positive
1041804.0,Portola Pharma Shares Tick Higher as Hearing William Blair Making Positive Comments,2017-01-05 09:59:00-05:00,PTLA,positive
1041805.0,18 Stocks Moving In Friday's Pre-Market Session,2016-12-30 08:16:00-05:00,PTLA,neutral
1041806.0,Physicians Likely To Support Portola's Betrixaban,2016-12-27 12:07:00-05:00,PTLA,positive
1041807.0,Technical Alert: Portola Pharmaceuticals Surrenders Some Of Friday's Gains,2016-12-27 10:49:00-05:00,PTLA,positive
1041808.0,"Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead",2016-12-27 09:21:00-05:00,PTLA,positive
1041809.0,5 Biggest Price Target Changes For Tuesday,2016-12-27 09:14:00-05:00,PTLA,neutral
1041810.0,Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral,2016-12-23 14:12:00-05:00,PTLA,positive
1041811.0,Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa,2016-12-19 08:00:00-05:00,PTLA,positive
1041812.0,"UPDATE: Portola Pharma Said APEX Substudy of Phase 3  Trial for Betrixaban Showed Significant Reduction in All-Cause Stroke, Ischemic Strong Through 77 Days of Follow Up",2016-11-14 16:58:00-05:00,PTLA,positive
1041813.0,Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban,2016-11-14 16:24:00-05:00,PTLA,negative
1041814.0,"Portola Pharmaceuticals Q3 Loss/Share $1.64 vs Est Loss/Share $1.10, Revenue $9.322M vs $4.1M Est",2016-11-07 17:05:00-05:00,PTLA,neutral
1041815.0,Portola Pharma Reports Q3 EPS $(1.64) vs $(1.05) in Same Qtr. Last Year,2016-11-07 16:36:00-05:00,PTLA,neutral
1041816.0,"7 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-11-01 10:03:00-04:00,PTLA,neutral
1041817.0,20 Stocks That Rallied Three Days On No News,2016-10-28 05:58:00-04:00,PTLA,negative
1041818.0,Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients,2016-10-25 08:08:00-04:00,PTLA,negative
1041819.0,10 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-20 06:50:00-04:00,PTLA,neutral
1041820.0,"Option Alert: PTLA Fri $25 Calls at the bid: Volume of 1,722 @ 2.101 vs 451 Open Interest",2016-09-22 13:26:00-04:00,PTLA,positive
1041821.0,Portola Pharmaceuticals Announces Encouraging Interim Results from Ongoing Phase 3b/4 ANNEXXA-4 Study of Factor Xa Inhibitor Antidote AndexXa in Patients with Acute Major Bleeding,2016-08-30 04:11:00-04:00,PTLA,positive
1041822.0,"Portola's AndexXa Still Approvable, But It Will Take Time",2016-08-19 11:45:00-04:00,PTLA,neutral
1041823.0,"Citi Sees 'Too Much Risk' In Portola Pharma, Downgrades To Neutral",2016-08-19 10:06:00-04:00,PTLA,negative
1041824.0,7 Biggest Price Target Changes For Friday,2016-08-19 09:32:00-04:00,PTLA,neutral
1041825.0,Benzinga's Top Downgrades,2016-08-19 08:59:00-04:00,PTLA,positive
1041826.0,Portola Pharma Reports Validation of MAA by EMA for IndexXa,2016-08-19 08:30:00-04:00,PTLA,neutral
1041827.0,"Citigroup Downgrades Portola Pharmaceuticals to Neutral, Lowers PT to $24.00",2016-08-19 03:28:00-04:00,PTLA,negative
1041828.0,12 Biggest Mid-Day Losers For Thursday,2016-08-18 14:22:00-04:00,PTLA,negative
1041829.0,Mid-Day Market Update: Sunedison Semiconductor Surges Following GlobalWafers Buyout; Auris Medical Shares Drop,2016-08-18 12:06:00-04:00,PTLA,neutral
1041830.0,Mid-Morning Market Update: Markets Mostly Flat; Wal-Mart Tops Q2 Views,2016-08-18 10:04:00-04:00,PTLA,positive
1041831.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-18 08:40:00-04:00,PTLA,neutral
1041832.0,PTLA Portola Pharmaceuticals Receives CRLfrom FDA for Biologics License Application for AndexXa,2016-08-18 04:14:00-04:00,PTLA,neutral
1041833.0,Watch These 7 Huge Put Purchases In Thursday Trade,2016-08-18 03:38:00-04:00,PTLA,positive
1041834.0,Wednesday's Market Wrap: Major Averages Record Small Gains,2016-08-17 17:02:00-04:00,PTLA,positive
1041835.0,Option Alert: PTLA Aug16 17.5 Puts: 500 @  ASK  $0.65: 809 traded vs 1935 OI: $23.62 Ref,2016-08-17 15:44:00-04:00,PTLA,positive
1041836.0,Portola Pharmaceuticals Reports Q2 EPS $(1.02) vs. Est. $(1.20),2016-08-09 17:22:00-04:00,PTLA,neutral
1041837.0,Portola Phamra Reports Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer,2016-06-01 08:03:00-04:00,PTLA,negative
1041838.0,Portola Pharma Risk-Reward Is Questionable,2016-05-31 10:37:00-04:00,PTLA,negative
1041839.0,"Credit Suisse Downgrades Portola Pharmaceuticals to Neutral, Lowers PT to $30.00",2016-05-31 04:40:00-04:00,PTLA,positive
1041840.0,Portola Pharmaceuticals Reveals Full Results Of Final Stage APEX Trial Of Betrixaban,2016-05-27 09:54:00-04:00,PTLA,neutral
1041841.0,"Portola Pharma Reports Full Results of Phase 3 APEX Study of Betrixaban; Plans to Submit NDA, MAA in 2H'16",2016-05-27 08:46:00-04:00,PTLA,neutral
1041842.0,Portola Pharma Says Will Present Phase 3 APEX Study Results of Betrixaban at ISTH Meeting,2016-04-06 08:05:00-04:00,PTLA,neutral
1041843.0,"Portola Pharmaceuticals, Daiichi Sankyo  Partner To Develop Andexanet Alfa With Edoxaban In Japan",2016-04-04 08:02:00-04:00,PTLA,neutral
1041844.0,"Deerfield Mgmt, L.P. Reports 5.48% Stake in Portola Pharmaceuticals in 13G",2016-03-30 11:53:00-04:00,PTLA,neutral
1041845.0,More Mid-Cap Biotech M&A May Be Coming,2016-03-29 11:32:00-04:00,PTLA,neutral
1041846.0,Stocks Hitting 52-Week Lows,2016-03-28 10:23:00-04:00,PTLA,negative
1041847.0,"Goldman Downgrades Portola Pharma To Neutral, Removes From Buy List",2016-03-28 09:35:00-04:00,PTLA,neutral
1041848.0,"Goldman Sachs Downgrades Portola Pharmaceuticals to Neutral, Lowers PT to $30.00, Removed From Conviction Buy List",2016-03-28 04:15:00-04:00,PTLA,negative
1041849.0,Mid-Afternoon Market Update: PVH Rises On Upbeat Results; Portola Pharmaceuticals Shares Slide,2016-03-24 14:37:00-04:00,PTLA,positive
1041850.0,Mid-Day Market Update: Crude Oil Down 2.8%; KB Home Shares Surge Following Strong Results,2016-03-24 12:15:00-04:00,PTLA,positive
1041851.0,What Was So Bad About Results Of Portola's APEX Trial For Betrixaban?,2016-03-24 11:58:00-04:00,PTLA,negative
1041852.0,"The Market In 5 Minutes: Thursday, March 24, 2016",2016-03-24 10:38:00-04:00,PTLA,neutral
1041853.0,Stocks Hitting 52-Week Lows,2016-03-24 10:15:00-04:00,PTLA,negative
1041854.0,Mid-Morning Market Update: Markets Open Lower; Finish Line Beats Q4 Expectations,2016-03-24 10:03:00-04:00,PTLA,negative
1041855.0,10 Stocks Moving In Thursday's Pre-Market Session,2016-03-24 08:15:00-04:00,PTLA,neutral
1041856.0,Portola Pharmaceuticals -30% Premarket @$20.00 Following Resumption of Trade After Announcing Phase III Betrixaban Results,2016-03-24 07:36:00-04:00,PTLA,neutral
1041857.0,Shares of Portola Pharma Were Halted to Announce Results from APEX Trial of Betrixaban; Will Resume Trade at 7:30 a.m. EDT,2016-03-24 07:08:00-04:00,PTLA,positive
1041858.0,Portola Pharma Offers Topline Results from Phase APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients,2016-03-24 07:05:00-04:00,PTLA,negative
1041859.0,"Portola Pharmaceuticals Announces Conference Call for Thursday, March 24, at 8:30 am ET to Provide Co Update",2016-03-24 04:27:00-04:00,PTLA,neutral
1041860.0,Portola Pharmaceuticals Reports Q4 Loss/Share $(1.23) vs $(1.12) Est; Revenue $4.414M vs $2.43M Est,2016-02-26 05:28:00-05:00,PTLA,neutral
1041861.0,"Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDA, Target FDA Action Date Aug. 17, 2016",2016-02-17 17:44:00-05:00,PTLA,positive
1041862.0,UPDATE: Portola Pharma Licensing Deals for Andexanet Alfa in Japan Valued at Up to $120M,2016-02-01 07:04:00-05:00,PTLA,positive
1041863.0,Bristol-Myers and Pfizer Announce Collaboration with Portoloa Pharma,2016-02-01 06:56:00-05:00,PTLA,neutral
1041864.0,Portola Pharma. Shares Falling,2016-01-13 10:32:00-05:00,PTLA,positive
1041865.0,"Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet Alfa, Includes Data From Portola's Phase 3 ANNEXA Studies",2015-12-18 08:04:00-05:00,PTLA,neutral
1041866.0,Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at #ASH2015,2015-12-05 10:28:00-05:00,PTLA,neutral
1041867.0,"Portola Reports Pricing Of Offering, 3.125M Shares At $48/Share",2015-12-04 08:01:00-05:00,PTLA,positive
1041868.0,Shares of Portola Pharma Down After Hours Following News of 2.6M Share Offering,2015-12-03 16:42:00-05:00,PTLA,positive
1041869.0,The New England Journal of Medicine Publishes Results of Portola Pharmaceuticals' Phase 3 ANNEXA Studies of Andexanet Alfa,2015-11-11 10:45:00-05:00,PTLA,neutral
1041870.0,Portola Pharmaceuticals Reports Phase 3 ANNEXA-R Part 2 Study Results to be Presented at American Heart Association Scientific Sessions 2015,2015-11-06 08:02:00-05:00,PTLA,neutral
1041871.0,Portola Pharma Reports Closing of Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Blood Clots,2015-10-30 08:03:00-04:00,PTLA,neutral
1041872.0,Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients,2015-10-13 08:04:00-04:00,PTLA,negative
1041873.0,Portola Pharmaceuticals Appoints Dr. David C. Stump to Board of Directors,2015-09-24 17:38:00-04:00,PTLA,neutral
1041874.0,Portola Pharmaceuticals Reports Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints,2015-09-15 08:01:00-04:00,PTLA,neutral
1041875.0,Portola Pharmaceuticals Reports In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not,2015-06-24 14:32:00-04:00,PTLA,neutral
1041876.0,Why Does Credit Suisse Like Portola Pharma?,2015-06-24 13:59:00-04:00,PTLA,positive
1041877.0,"Credit Suisse Assumes Portola Pharmaceuticals at Outperform, Announces $51.00 PT",2015-06-24 07:05:00-04:00,PTLA,positive
1041878.0,"Credit Suisse Initiates Coverage on Portola Pharmaceuticals at Outperform, Announces $51.00 PT",2015-06-23 16:24:00-04:00,PTLA,positive
1041879.0,"Portola, Bristol-Myers Squibb, Pfizer Announce Complete Phae 3 ANNEXA-A Studya Results",2015-06-22 08:47:00-04:00,PTLA,neutral
1041880.0,2 Small Biotechs This Pro Is Watching,2015-05-29 15:29:00-04:00,PTLA,neutral
1041881.0,Portola Pharmaceuticals Showcases Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib,2015-05-29 08:07:00-04:00,PTLA,negative
1041882.0,Portola Pharma Reports Will Present Data on Dual Kinase Inhibitor Cerdulatinib at ASCO,2015-05-18 08:05:00-04:00,PTLA,negative
1041883.0,Portola Pharmaceuticals Announces Collaboration With Ora on PRT2761 in Ophthalmic Diseases,2015-05-05 08:06:00-04:00,PTLA,neutral
1041884.0,Portola Pharma Reports Collaboration with Ora for PRT2761 in Ophthalmic Diseases,2015-05-05 08:02:00-04:00,PTLA,neutral
1041885.0,Portola Pharmaceuticals Reports Brand New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint for Prolonged Reversal of Factor Xa Inhibitor Eliquis (apixaban),2015-04-08 08:01:00-04:00,PTLA,positive
1041886.0,Portola Pharmaceuticals Announces Proposed Offering of Common Stock,2015-03-09 16:26:00-04:00,PTLA,neutral
1041887.0,Portola Pharma Announces Offering of $100M Stock,2015-03-09 16:13:00-04:00,PTLA,neutral
1041888.0,"Portola Reports Q4 EPS -$0.82 Vs Est -$0.90, Announce Positive Phase 3 ANNEXA-R Study",2015-03-02 08:05:00-05:00,PTLA,positive
1041889.0,Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa,2015-02-26 08:00:00-05:00,PTLA,neutral
1041890.0,Portola Pharmaceuticals Initiates Single-arm Phase 4 Study,2015-01-12 08:16:00-05:00,PTLA,neutral
1041891.0,What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts,2015-01-09 12:43:00-05:00,PTLA,neutral
1041892.0,Friday's Morning Movers: Earnings Start To Trickle In,2015-01-09 10:06:00-05:00,PTLA,neutral
1041893.0,Portola Pharma Announces Phase 3 Trial Met Primary Endpoints,2015-01-09 08:05:00-05:00,PTLA,neutral
1041894.0,"UPDATE: Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)",2014-11-17 08:13:00-05:00,PTLA,positive
1041895.0,"Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)",2014-11-17 08:12:00-05:00,PTLA,positive
1041896.0,"Portola , Bristol-Myers Squibb, Pfizer Report Statistically Significant Results from First Part of Phase 3 ANNEXA-A Studies of Andexanet Alfa with Eliquis",2014-11-17 08:03:00-05:00,PTLA,positive
1041897.0,Portola Pharma Reports Q3 EPS of $(0.86) vs $(0.92) Est; Revenue of $2.43M vs $2.73M Est,2014-11-10 16:16:00-05:00,PTLA,neutral
1041898.0,Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza,2014-10-16 16:08:00-04:00,PTLA,positive
1041899.0,Portola Prices 6.25M Share Offering @$26.00/Share,2014-10-02 22:19:00-04:00,PTLA,positive
1041900.0,Portola Pharmaceuticals Announces Proposed Offering of Common Stock For Gross Proceeds Of $160M,2014-10-01 16:26:00-04:00,PTLA,negative
1041901.0,S-3 from Portola Pharma Shows Registration for 10M Share Common Stock Shelf Offering,2014-10-01 16:10:00-04:00,PTLA,positive
1041902.0,"Midday Gainers From October 1 - Angie's List Inc, Tekmira Pharmaceuticals Corporation And More",2014-10-01 12:52:00-04:00,PTLA,neutral
1041903.0,Morning Market Movers ,2014-10-01 09:39:00-04:00,PTLA,neutral
1041904.0,Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance ,2014-10-01 08:11:00-04:00,PTLA,positive
1041905.0,UPDATE: Portola Will Receive Upfront Payment and Be Eligible for Milestone Payments,2014-07-07 14:12:00-04:00,PTLA,neutral
1041906.0,Portola Pharma Announces Entered Into Clinical Collab. Deal with Daiichi Sankyo for Phase 3 Studies of Andexanet Alfa and Edoxaban,2014-07-07 14:12:00-04:00,PTLA,neutral
1041907.0,"8-K from Portola Pharma Shows Co. Entered Commercial Supply Deal with CMC ICOS Biologics on Jul. 1st, Co. Will Make Immediate Upfront Payment of $10M, to Make Reservation Payment of $4.6M in Nov.",2014-07-02 17:05:00-04:00,PTLA,neutral
1041908.0,Top 4 Stocks In The Biotechnology Industry With The Highest EPS,2014-06-25 04:54:00-04:00,PTLA,positive
1041909.0,Portola Pharma Announces Positive Results From Phase II Therapy With Andexanet Alfa and Enoxaparin,2014-06-11 08:04:00-04:00,PTLA,positive
1041910.0,Portola To Announce Syk-JAK Results at American Society of Clinical Oncology May 30-June 3,2014-05-14 17:04:00-04:00,PTLA,neutral
1041911.0,"Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban",2014-03-27 08:01:00-04:00,PTLA,negative
1041912.0,"Portola Pharma Begins Phase 3 Study of Andexanet Alfa, Sees Initial Data from Study in Q4'14, Sees Data from Second Part in Early '15",2014-03-19 08:22:00-04:00,PTLA,neutral
1041913.0,"Morgan Stanley Maintains Overweight on Portola Pharma, Raises PT to $40.00",2014-03-04 07:17:00-05:00,PTLA,negative
1041914.0,"Portola Pharma Announces Deal with Bayer, Janssen for Phase 3 Studies of Andexanet Alfa, XARELTO(R)",2014-02-03 08:03:00-05:00,PTLA,neutral
1041915.0,"Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)",2014-02-03 08:02:00-05:00,PTLA,positive
1041916.0,"Portola Pharma Announces Second Clinical Pact with Bristol-Myers, Will Study Andexanet Alfa with Eliquis, Will Receive Upfront, Milestone Payments",2014-01-13 08:05:00-05:00,PTLA,neutral
1041917.0,"Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO",2013-12-09 11:04:00-05:00,PTLA,neutral
1041918.0,Portola Pharma Reports FDA Breakthrough Therapy Designation for Andexanet Alfa (PRT4445),2013-11-25 08:01:00-05:00,PTLA,neutral
1041919.0,Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*),2013-11-11 08:03:00-05:00,PTLA,positive
1041920.0,Portola Pharma Reports Q3 EPS of $(0.53) vs $(0.68) Est,2013-11-05 16:35:00-05:00,PTLA,neutral
1041921.0,Portola Pharma Prices 6.4M Shares at $23.75/Share,2013-10-17 08:34:00-04:00,PTLA,positive
1041922.0,"SEC Filing from Portola Pharma Shows Prospectus for 4.46M Shares by Co., 1.91M Shares by Selling Holders",2013-10-16 17:33:00-04:00,PTLA,positive
1041923.0,Amended S-1 Filing from Portola Pharma Shows Co. to Offer 4.8M Shares for Selling Holders,2013-10-16 06:49:00-04:00,PTLA,positive
1041924.0,Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445,2013-10-14 17:06:00-04:00,PTLA,neutral
1041925.0,Stocks Hitting 52-Week Highs,2013-10-03 10:40:00-04:00,PTLA,neutral
1041926.0,Portola Pharmaceuticals to Present Preclinical Data on Andexanet Alfa,2013-08-29 08:05:00-04:00,PTLA,neutral
1041927.0,Portola Pharma Reports Q2 EPS of $(1.47) vs $(0.71) Est,2013-08-15 07:55:00-04:00,PTLA,neutral
1041928.0,Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R) ,2013-07-02 07:31:00-04:00,PTLA,positive
1041929.0,Portola to Initiate Phase 2 Study Evaluating the Safety and Effectiveness of Its Factor Xa Inhibitor Antidote PRT4445 in Reversing the Anticoagulant Activity of Investigational Factor Xa Inhibitor Edoxaban ,2013-06-26 16:07:00-04:00,PTLA,positive
1041930.0,"Portola Announces Oral Presentation of Phase 2 Data on PRT4445, Factor Xa Inhibitor Antidote, at 2013 International Society on Thrombosis and Haemostasis Congress ",2013-06-26 08:05:00-04:00,PTLA,negative
1041931.0,UPDATE: Credit Suisse Initiates Portola Pharmaceuticals at Outperform Rating Ahead of PIII APEX Trial,2013-06-17 09:45:00-04:00,PTLA,positive
1041932.0,"Credit Suisse Initiates Coverage on Portola Pharma at Outperform, Announces $30.00 PT",2013-06-17 09:09:00-04:00,PTLA,positive
1041933.0,UPDATE: Morgan Stanley Initiates Portola Pharmaceuticals at Overweight on Drugs Potentially Fulfilling Serious Medical Need ,2013-06-17 08:34:00-04:00,PTLA,negative
1041934.0,Benzinga's Top Initiations,2013-06-17 07:15:00-04:00,PTLA,positive
1041935.0,"Morgan Stanley Initiates Coverage on Portola Pharma at Overweight, Announces $32.00 PT",2013-06-17 06:43:00-04:00,PTLA,negative
1041936.0,"Mid-Morning Market Update: Markets Tumble, Shuanghui To Acquire Smithfield Foods",2013-05-29 10:24:00-04:00,PTLA,neutral
1041937.0,Trading Released/Resumed: (NASDAQ: PTLA) Reason Not Available,2013-05-28 12:09:00-04:00,PTLA,neutral
1041938.0,Portola Pharma Opens for Trade at $15.25/Share After Pricing at $14.50,2013-05-22 11:01:00-04:00,PTLA,neutral
1041939.0,"Portola Pharma IPO to Open for Quote at 10:45AM EDT, to Open at 11AM; Priced 8.42M Shares at $14.50/Share, Initial Offering Was for 6.9M Shares in $13-16/Share Range",2013-05-22 10:26:00-04:00,PTLA,positive
